PMID- 26489077 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20161230 IS - 1945-8932 (Electronic) IS - 1945-8932 (Linking) VI - 30 IP - 1 DP - 2016 Jan-Feb TI - Antiallergic effects of anti-interleukin-33 are associated with suppression of immunoglobulin light chain and inducible nitric oxide synthase. PG - 17-22 LID - 10.2500/ajra.2015.29.4251 [doi] AB - OBJECTIVE: We aimed to find novel genes that are significantly induced in allergic mice and that are significantly downregulated with anti-interleukin (IL) 33 treatment. METHODS: Thirty-six mice were allocated into each of group A (intraperitoneal [i.p.]) sensitized and intranasally challenged to saline solution), group B (sensitized and challenged to ovalbumin), group C (sensitized and challenged with ovalbumin, and null treatment with i.p. saline solution), and group D (sensitized and challenged with ovalbumin, and treatment with anti-IL-33 i.p. injection). We counted the number of nose-scratching in 10 minutes, serum ovalbumin-specific immunoglobulin E (IgE), and titers of cytokines (IL-1, IL-4, IL-5, IL-10, IL-13) in bronchoalveolar lavage fluid. By using one whole lung from each mouse, we performed microarray analysis and real-time polymerase chain reaction. RESULTS: group D showed a significantly reduced nose-scratching events and lower serum ovalbumin-specific IgE compared with groups B and C. All the cytokines in the bronchoalveolar lavage fluid were significantly decreased after anti-IL-33 treatment. Microarray analysis revealed that group B (immunoglobulin free light chain [IgFLC], 89.1 times; nitric oxide synthase [NOS] 2, 11.5 times) and group C (IgFLC, 141.6 times; NOS2, 11.7 times) had significantly increased expression of IgFLC and NOS2 genes compared with group A. After anti-IL-33 treatment, group D showed significantly decreased expression of both IgFLC (49.3 times) and NOS2 (6.5 times). In real-time polymerase chain reaction, groups B and C had significantly increased expression of these genes (IgFLC, 10.4 times and 29 times, respectively; NOS2, 3.8 times and 4.5 times, respectively). After treatment, group D showed significantly decreased expression of IgFLC (5.0 times) and NOS2 (2.5 times). CONCLUSION: The antiallergic effect of anti-IL-33 can be explained by suppression of IgFLC and NOS2 in a murine model of allergic rhinitis. FAU - Park, Chang-Shin AU - Park CS AD - Department of Pharmacology, Hypoxia-Related Disease Research Center, Inha Research Institute for Medical Sciences, Inha University College of Medicine, Incheon, Republic of Korea. FAU - Jang, Tae Young AU - Jang TY FAU - Heo, Min-Jeong AU - Heo MJ FAU - Jung, Ah-Yeoun AU - Jung AY FAU - Kim, Young Hyo AU - Kim YH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151015 PL - United States TA - Am J Rhinol Allergy JT - American journal of rhinology & allergy JID - 101490775 RN - 0 (Antibodies, Blocking) RN - 0 (Immunoglobulin Light Chains) RN - 0 (Interleukin-33) RN - 37341-29-0 (Immunoglobulin E) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.13.39 (Nos2 protein, mouse) SB - IM MH - Animals MH - Antibodies, Blocking/*therapeutic use MH - Bronchoalveolar Lavage Fluid/immunology MH - Female MH - *Gene Expression Regulation/drug effects MH - Humans MH - Hypersensitivity/immunology/*therapy MH - Immunoglobulin E/blood MH - Immunoglobulin Light Chains/genetics/*metabolism MH - Immunotherapy/*methods MH - Interleukin-33/*immunology MH - Mice MH - Mice, Inbred BALB C MH - Microarray Analysis MH - Nitric Oxide Synthase Type II/genetics/*metabolism EDAT- 2015/10/22 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/10/22 06:00 PHST- 2015/10/22 06:00 [entrez] PHST- 2015/10/22 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - content-4251 [pii] AID - 10.2500/ajra.2015.29.4251 [doi] PST - ppublish SO - Am J Rhinol Allergy. 2016 Jan-Feb;30(1):17-22. doi: 10.2500/ajra.2015.29.4251. Epub 2015 Oct 15.